Drugs and Devices

FDA warns of drug interactions between Victrelis and ritonavir-boosted human immunodeficiency virus (HIV) protease inhibitors

On Feb. 7, the U.S. Food and Drug Administration announced that drug interactions between the hepatitis C virus protease inhibitor Victrelis (boceprevir) and certain ritonavir-boosted human immunodeficiency virus protease inhibitors (atazanavir, lopinavir, darunavir) can potentially reduce the effectiveness of these medications when they are used in combination. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Newsletter Subscribe

  • This field is for validation purposes and should be left unchanged.

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares